GlobeNewswire Inc | Nov 16, 2020 08:00AM EST

November 16, 2020

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V.(Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonicsand Triclonics), today announced thatBill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference onTuesday, November 17, 2020at14:40 p.m. GMT/9:40 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.

About MerusMerusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonicsare manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus website,www.merus.nland https://twitter.com/MerusNV.

Investor and Media Inquiries:

Jillian ConnellMerus N.V.Investor Relations and Corporate Communications617-955-4716j.connell@merus.nl